Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL

INTRODUCTION: versus HyBryte™ through 12 weeks of treatment, and (ii) to better understand the impact of HyBryte™ application on the measurement of modified Composite Assessment of Index Lesion Severity (mCAILS). METHODS: for 12 weeks. RESULTS: had skin reactions, including one case which led to study withdrawal. CONCLUSIONS: in patients with CTCL. HyBryte™ showed higher treatment success rates and was better tolerated. TRIAL REGISTRATION: ClinicalTrials.gov, NCT06149247; registered November 20, 2023.